Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04090710
Title SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ontario Clinical Oncology Group (OCOG)
Indications

renal cell carcinoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: senior | adult | child
Covered Countries CAN


No variant requirements are available.